Please login to the form below

Not currently logged in
Email:
Password:

AZ's Symbicort suffers setback

AstraZeneca has been denied approval by the FDA for the use of its asthma drug Symbicort in children aged 6-11 years old

AstraZeneca has been denied approval by the US Food and Drug Administration (FDA) for the use of its asthma drug Symbicort in children aged 6-11 years old.

The company received a Complete Response Letter (CRL) from the FDA that said the company had failed to provide adequate data to establish the appropriate doses of the individual components of Symbicort, budesonide and formoterol, and to establish how the components contribute to the complete product when used in children aged 6-11 years old. AstraZeneca will send the FDA a response to the CRL in due course.

Symbicort was approved in the US for use in children over 12 years old for long-term maintenance of asthma in July 2009. In February 2009, Symbicort was approved in the US for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema.

Current treatment with Symbicort is not affected by the CRL.

7th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics